Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Juli 2026 08:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase

KNOXVILLE, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- VisiRose, Inc. (“VisiRose” or the “Company”), the clinical-stage ophthalmology subsidiary of Provectus Biopharmaceuticals, Inc. (“Provectus”)...
30. Juni 2026 08:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic...
14. Januar 2025 08:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose,...
11. Dezember 2024 09:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”),...